July 11, 2014—The Senate Finance Committee’s Democratic chairman and a senior Republican member want Gilead Sciences to justify the $1,000-a-day price of its hepatitis C virus drug Sovaldi.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)